Literature DB >> 19804981

Synthesis, cytotoxicity and human telomerase inhibition activities of a series of 1,2-heteroannelated anthraquinones and anthra[1,2-d]imidazole-6,11-dione homologues.

Hsu-Shan Huang1, Tsung-Chih Chen, Ruei-Huei Chen, Kuo-Feng Huang, Fong-Chun Huang, Jing-Ru Jhan, Chun-Liang Chen, Chia-Chung Lee, Yang Lo, Jing-Jer Lin.   

Abstract

A series of 1,2-heteroannelated anthraquinones and anthra[1,2-d]imidazole-6,11-dione tetracyclic analogues with different side chain were prepared using an various synthetic route via acylation, cyclization, condensation, and intramolecular heterocyclization. Tetracyclic system containing alkyl and aryl, aromatic and heterocyclic, linear and cyclic, polar and apolar, and basic and acids residues were incorporated. They were evaluated for their effects on telomerase activity, hTERT expression, cell proliferations, and in vitro cytotoxicity against NCI's 60 cell line human tumor screen. Compounds 4, 11, 12, 14, 15, 16, 17, 19, 20, 23, 25, and 26 were selected by the NCI for one dose screening program and further studies on 4, 23 and 25 where the curves cross these lines represent the interpolated values to cause 50% growth inhibition (GI(50)), total growth inhibition (TGI) and 50% cell killing (LC(50)), respectively. Further studies did not reveal any compound that showed potent and significant on telomerase inhibitory activity and hTERT repressing ability. Comparative testing of these compounds in the NCI's screen revealed varying levels of potency and differential cytotoxicity, apparently related to the unsaturation levels in and substitution patterns on the core ring system. It appeared that addition of a fourth planar aromatic system to a tricyclic chromophore might enhances potent cytotoxic agents, at a level equivalent to a second side chain in one of the tricyclic series. Although the exact mechanism of how this pharmacophore contributes to its activity is still unclear, however, the group in the extended arm of the tetracyclic system might contribute to proper binding to the residues within the grove of G-quadruplex structure.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19804981     DOI: 10.1016/j.bmc.2009.09.033

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  10 in total

1.  A novel compound NSC745885 exerts an anti-tumor effect on tongue cancer SAS cells in vitro and in vivo.

Authors:  Yuan-Wu Chen; Hsu-Shan Huang; Yi-Shing Shieh; Kuo-Hsing Ma; Shing-Hwa Huang; Dueng-Yuan Hueng; Huey-Kang Sytwu; Gu-Jiun Lin
Journal:  PLoS One       Date:  2014-08-15       Impact factor: 3.240

2.  Novel Anthra[1,2-c][1,2,5]Thiadiazole-6,11-Diones as Promising Anticancer Lead Compounds: Biological Evaluation, Characterization & Molecular Targets Determination.

Authors:  Ahmed Atef Ahmed Ali; Yu-Ru Lee; Tsung-Chih Chen; Chun-Liang Chen; Chia-Chung Lee; Chia-Yang Shiau; Chiao-Hsi Chiang; Hsu-Shan Huang
Journal:  PLoS One       Date:  2016-04-21       Impact factor: 3.240

Review 3.  Thiadiazole derivatives as anticancer agents.

Authors:  Monika Szeliga
Journal:  Pharmacol Rep       Date:  2020-09-03       Impact factor: 3.024

4.  Anticancer Activities of 9-chloro-6-(piperazin-1-yl)-11H-indeno[1,2-c] quinolin-11-one (SJ10) in Glioblastoma Multiforme (GBM) Chemoradioresistant Cell Cycle-Related Oncogenic Signatures.

Authors:  Ntlotlang Mokgautsi; Yu-Cheng Kuo; Sung-Ling Tang; Feng-Cheng Liu; Shiang-Jiun Chen; Alexander T H Wu; Hsu-Shan Huang
Journal:  Cancers (Basel)       Date:  2022-01-05       Impact factor: 6.639

5.  In vivo Pharmacokinetic and Anticancer Studies of HH-N25, a Selective Inhibitor of Topoisomerase I, and Hormonal Signaling for Treating Breast Cancer.

Authors:  Bashir Lawal; Yu-Cheng Kuo; Maryam Rachmawati Sumitra; Alexander T H Wu; Hsu-Shan Huang
Journal:  J Inflamm Res       Date:  2021-09-22

6.  Transcriptomic-Based Identification of the Immuno-Oncogenic Signature of Cholangiocarcinoma for HLC-018 Multi-Target Therapy Exploration.

Authors:  Bashir Lawal; Yu-Cheng Kuo; Sung-Ling Tang; Feng-Cheng Liu; Alexander T H Wu; Hung-Yun Lin; Hsu-Shan Huang
Journal:  Cells       Date:  2021-10-25       Impact factor: 6.600

7.  New approaches of PARP-1 inhibitors in human lung cancer cells and cancer stem-like cells by some selected anthraquinone-derived small molecules.

Authors:  Yu-Ru Lee; Dah-Shyong Yu; Ya-Chun Liang; Kuo-Feng Huang; Shih-Jie Chou; Tsung-Chih Chen; Chia-Chung Lee; Chun-Liang Chen; Shih-Hwa Chiou; Hsu-Shan Huang
Journal:  PLoS One       Date:  2013-02-25       Impact factor: 3.240

8.  Identification of a new class of WNT1 inhibitor: Cancer cells migration, G-quadruplex stabilization and target validation.

Authors:  Lien-Cheng Chang; Tsung-Chih Chen; Shiag-Jiun Chen; Chun-Liang Chen; Chia-Chung Lee; Shih-Hsiung Wu; Yun Yen; Hsu-Shan Huang; Jing-Jer Lin
Journal:  Oncotarget       Date:  2016-10-18

9.  Identification and preclinical evaluation of the small molecule, NSC745887, for treating glioblastomas via suppressing DcR3-associated signaling pathways.

Authors:  Li-Yun Fann; Ying Chen; Da-Chen Chu; Shao-Ju Weng; Heng-Cheng Chu; Alexander T H Wu; Jiann-Fong Lee; Ahmed Atef Ahmed Ali; Tsung-Chih Chen; Hsu-Shan Huang; Kuo-Hsing Ma
Journal:  Oncotarget       Date:  2017-12-27

10.  CC12 Induces Apoptotic Cell Death and Cell Cycle Arrest in Human Glioblastoma Cell Lines and Mouse Xenograft Model.

Authors:  Li-Yun Fann; Jui-Hu Shih; Jen-Ho Tseng; Hsu-Shan Huang; Sheng-Huang Hsiao
Journal:  Molecules       Date:  2020-04-14       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.